FDG PET imaging of childhood sarcomas

Pediatric Blood and Cancer

Volumn 54, Issue 2, 2010, Pages 222-227

  Mody, Rajen J ^a   Bui, Chuong ^a   Hutchinson, Raymond J ^a   Yanik, Greg A ^a   Castle, Valerie P ^a   Frey, Kirk A ^a   Shulkin, Barry L ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Ewing; FDG; Fluorodeoxyglucose; Pediatric; PET; Rhabdomyosarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER RELAPSE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SARCOMA; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; NEUROECTODERMAL TUMORS, PRIMITIVE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 74849118593     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22307     Document Type: Article

References (24)

1. Bernstein M,KovarH, Paulussen M, et al. Ewing sarcoma family of tumors: Ewing sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. pp. 1003-1032.
2. Wexler LH, Meyer WH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. pp. 972-1001.
3. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002; 32:35-46.
4. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995;194:495-500.
5. Hawkins DS, Rajendran JG, Conrad EU III, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002;94:3277-3284.
6. Franzius C, Juergens KU, Vormoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. Am J Roentgenol 2006; 186:581-582.
7. McCarville MB, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. Am J Roentgenol 2005;184: 1293-1304.
8. Wegner EA, Barrington SF, Kingston JE, et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging 2005;32:23-30.
9. Ben Arush MW, Bar SR, Postovsky S, et al. Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol 2006;28:440-445.
10. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-8834.
11. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: Form and function. Radiology 2007;242:360-385.
12. Iagaru A, Quon A, McDougall IR, et al. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas. Clin Nucl Med 2006;31:754-760.
13. Iagaru A, Chawla S, Menendez L, et al. 18F-FDG PETand PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006;27:795-802.
14. Gyorke T, Zajic T, Lange A, et al. Impact ofFDGPET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 2006;27:17-24.
15. Gerth HU, Juergens KU, Dirksen U, et al. Significant benefit of multimodal imaging: PET/CT compared with PETalone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007; 48:1932-1939.
16. Goodin GS, Shulkin BL, Kaufman RA, et al. PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease.AmJ Roentgenol 2006;187:1124-1128.
17. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-348.
18. Eary JF,O'Sullivan F, PowitanY, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: A retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154.
19. Keyes JW, Jr. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-1839.
20. Cobben DC, Elsinga PH, Suurmeijer AJ, et al. Detection and grading of soft tissue sarcomas of the extremities with (18)F-3′-fluoro-3′- deoxy-L-thymidine. Clin Cancer Res 2004;10:1685-1690.
21. Been LB, Suurmeijer AJ, Elsinga PH, et al. 18F-fluorodeoxythymidine PET for evaluating the response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcomas. J Nucl Med 2007;48:367-372.
22. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
23. Plaat B, Kole A, Mastik M, et al. Protein synthesis rate measured with L-[1-11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med 1999;26:328-332.
24. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.